About | 16p13.11 deletion study - The Girirajan Laboratory

The 16p13.11 deletion is significantly associated with neurodevelopmental diseases, and is observed in approximately 1 in 2000 live births. The primary 16p13.11 deletion spans 7 genes of interest: BMERB1, MARF1, NDE1, MYH11, FOPNL, ABCC1 and ABCC6 (right figure).

A wide array of clinical features have been associated with the 16p13.11 deletion. Individuals with the deletion are likely to exhibit developmental and speech delay, learning disabilities, small head size (microcephaly), and seizures (including some individuals diagnosed with West syndrome-related seizures). Skeletal and cardiac defects as well as dysmorphic features have also been observed in deletion carriers. However, individuals with the deletion do not share the same sets of symptoms, which indicates that this deletion is non-syndromic.

Individuals with the deletion have a sensitized genomic background rendering them vulnerable to multiple neurodevelopmental disorders such as intellectual disability, autism, and epilepsy. We are currently studying the 16p13.11 deletion as a paradigm to understand the complex genetics of developmental disorders. We hypothesize that genetic variants near or within the CNV interval and/or at a second site elsewhere in the genome contribute to the phenotypic outcome of disorders association with the deletion. Because the 16p13.11 deletion is inherited from parents in >75% of cases, assessing family history is essential to understanding the disease.

Most genomic deletions are the result of non-allelic homologous recombination (NAHR) between large (larger than 10kb) and highly similar sequences of DNA called segmental duplications. Several chromosomes are enriched in these types of DNA sequences, including the short arm of chromsome 16 (16p). This leads to a higher frequency of these rearrangements and therefore genomic disorders associated with this variation.

Study of the 16p13.11 deletion continues to be promising in understanding the variable clinical features associated with the disorder, and will lay a foundation to provide better treatment methods to patients in the years to come.

How to Participate

We are currently recruiting individuals with the 16p13.11 deletion and their family members for this study, and invite you to participate if your child or loved one has been affected by the deletion. The following link leads to an initial questionnaire, which we will use to obtain some preliminary information about you and your family members who carry the 16p13.11 deletion.

We estimate that the survey will take approximately 15 minutes to complete. We note that participation in this questionnaire is completely voluntary. All answers will be kept strictly confidential, and protected to the maximum extent as required by law.

After you complete the questionnaire, we will contact you directly with further information on our study. Your participation in this study will be very important in understanding the connections between genetic variants and the symptoms identified in individuals carrying the 16p13.11 deletion.

Link to 16p13.11 deletion questionnaire

Further Resources

Rare Chromosome Disorder Support Group: 16p13.11 microdeletions

European Journal of Human Genetics: Clinical utility gene card for: 16p13.11 microdeletion syndrome

Additional reading

Rare variants in the genetic background modulate cognitive and developmental phenotypes in individuals carrying disease-associated variants.
Pizzo L, Jensen M, Polyak A, Rosenfeld JA, Mannik K, Krishnan A, McCready E, Pichon O, Le Caignec C, Van Dijck A, Pope K, Voorhoeve E, Yoon J, Stankiewicz P, Cheung SW, Pazuchanics D, Huber E, Kumar V, Kember R, Mari F, Curró A, Castiglia L, Galesi O, Avola E, Mattina T, Fichera M, Mandarà L, Vincent M, Nizon M, Mercier S, Bénéteau C, Blesson S, Martin-Coignard D, Mosca-Boidron A, Caberg JH, Bucan M, Zeesman S, Nowaczyk MJM, Lefebvre M, Faivre L, Callier P, Skinner C, Keren B, Perrine C, Prontera P, Marle N, Renieri A, Reymond A, Kooy RF, Isidor B, Schwartz C, Romano C, Sistermans E, Amor DJ, Andrieux J, Girirajan S.

We assessed the contribution of rare variants in the genetic background toward variability of neurodevelopmental phenotypes in individuals with rare copy-number variants (CNVs) and gene-disruptive variants. We analyzed quantitative clinical information, exome sequencing, and microarray data from 757 probands and 233 parents and siblings who carry disease-associated variants. The number of rare likely deleterious variants in functionally intolerant genes ("other hits") correlated with expression of neurodevelopmental phenotypes in probands with 16p12.1 deletion and in autism probands carrying gene-disruptive variants compared with their carrier family members. Probands with 16p12.1 deletion and a strong family history presented more severe clinical features and higher burden of other hits compared with those with mild/no family history. The number of other hits also correlated with severity of cognitive impairment in probands carrying pathogenic CNVs (n=53) or de novo pathogenic variants in disease genes (n=290), and negatively correlated with head size among 80 probands with 16p11.2 deletion. These co-occurring hits involved known disease-associated genes such as SETD5, AUTS2, and NRXN1, and were enriched for cellular and developmental processes. Accurate genetic diagnosis of complex disorders will require complete evaluation of the genetic background even after a candidate disease-associated variant is identified.

Phenotypic heterogeneity of genomic disorders and rare copy-number variants.
Girirajan S, Rosenfeld JA, Coe BP, Parikh S, Friedman N, Goldstein A, Filipink RA, McConnell JS, Angle B, Meschino WS, Nezarati MM, Asamoah A, Jackson KE, Gowans GC, Martin JA, Carmany EP, Stockton DW, Schnur RE, Penney LS, Martin DM, Raskin S, Leppig K, Thiese H, Smith R, Aberg E, Niyazov DM, Escobar LF, El-Khechen D, Johnson KD, Lebel RR, Siefkas K, Ball S, Shur N, McGuire M, Brasington CK, Spence JE, Martin LS, Clericuzio C, Ballif BC, Shaffer LG, Eichler EE.

Some copy-number variants are associated with genomic disorders with extreme phenotypic heterogeneity. The cause of this variation is unknown, which presents challenges in genetic diagnosis, counseling, and management. We analyzed the genomes of 2312 children known to carry a copy-number variant associated with intellectual disability and congenital abnormalities, using array comparative genomic hybridization. Among the affected children, 10.1% carried a second large copy-number variant in addition to the primary genetic lesion. We identified seven genomic disorders, each defined by a specific copy-number variant, in which the affected children were more likely to carry multiple copy-number variants than were controls. We found that syndromic disorders could be distinguished from those with extreme phenotypic heterogeneity on the basis of the total number of copy-number variants and whether the variants are inherited or de novo. Children who carried two large copynumber variants of unknown clinical significance were eight times as likely to have developmental delay as were controls. Among affected children, inherited copy-number variants tended to co-occur with a second-site large copy-number variant. Boys were more likely than girls to have disorders of phenotypic heterogeneity, and mothers were more likely than fathers to transmit second-site copy-number variants to their offspring.